Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 23: Perindopril - Verträglichkeit Abb. 24: EUROPA-Studie - Studienziel Abb. 25: EUROPA-Studie - Endpunkte Aktuelles Bild - Abb. 26: EUROPA-Studie - Studiendesign Abb. 27: EUROPA-Studie - Patientenauswahl Abb. 28: EUROPA-Studie - KHK Abb. 29: EUROPA-Studie - Charakteristik Zum letzten Bild
Abbildung 26: EUROPA-Studie - Studiendesign
After the run-in period of 2 weeks patients received 4 mg of perindopril once daily in the morning in addition to their usual medication. At 4 weeks, the thrid visit, patients were randomized double-blind to perindopril 8 mg or placebo, and continued their treatment until the last patients included complete the 4-year follow-up period.
 
EUROPA-Studie - Studiendesign
Vorheriges Bild Nächstes Bild   


Abbildung 26: EUROPA-Studie - Studiendesign
After the run-in period of 2 weeks patients received 4 mg of perindopril once daily in the morning in addition to their usual medication. At 4 weeks, the thrid visit, patients were randomized double-blind to perindopril 8 mg or placebo, and continued their treatment until the last patients included complete the 4-year follow-up period.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung